All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Lilly and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
5-year follow-up: Mosunetuzumab in patients with heavily pretreated R/R FL
Do you know... Which of the following statements accurately describes efficacy outcomes in patients with POD24 who received mosunetuzumab for R/R FL in the phase II GO29781 trial?
Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody that is approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of systemic therapy.1–3 Patients with R/R FL received fixed-duration mosunetuzumab for 8 or 17 cycles (dependent on response) in the pivotal phase II GO29781 trial, which met its primary endpoint at a median follow-up of 18.2 months.4 During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, Elizabeth Budde presented 5-year data from the GO29781 trial.1
Fixed-duration mosunetuzumab demonstrated durable long-term efficacy in this population, with a complete response rate (CRR) of 60% and overall response rate (ORR) of 78% at a median follow-up of 60.2 months.1 Efficacy outcomes were similar to the whole cohort in high-risk patients who had progressed within 24 months of first-line therapy (POD24).1 In patients with a complete response (CR), median progression-free survival (PFS) was higher (61 months) than in the overall cohort (24 months).1 B-cell and IgM recovery was observed and sustained in patients with a CR, and mosunetuzumab had a manageable safety profile. Fixed-duration mosunetuzumab remains a viable option for heavily pre-treated patients with R/R FL.1
This educational resource is independently supported by Roche. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource
References
